Supplementary Table 1.
Discovery and Validation Sample Cohorts
| Discovery RNAseq samples | Number of samples | Median age at diagnosis, y (range) | Gender distribution | Cancer stage distribution |
|---|---|---|---|---|
| EACa | 49 | 65 (36 - 88) | 89% (male) 11% (female) | Stage I (17.9%), Stage II (19.6%), Stage III (46.4%), Stage IV (16.1%) |
| Nondysplastic stable Barrett's esophagusb | 18 | 56 (18-84) | 94% (male) 6% (female) | NA |
| Normal esophageal squamous (SQ)c | 11 | 64 (45-83) | 90% (male) 10% (female) | NA |
| Normal gastric (GAST) | 11 | 63 (36-82) | 82% (male) 18% (female) | NA |
| Total | 89 |
| Validation samples | Number of samples | Median age at diagnosis, y (range) | Gender distribution | Cancer stage distribution |
|---|---|---|---|---|
| EACd | 170 | 64 (34–89) | 77% (male) 15% (female) | Stage I (14.1%), Stage II (16.8%), Stage III (52.2%), Stage IV (15.0%) |
| Normal esophageal squamous (SQ) | 465 | 64 (34 –89) | 77% (male) 15% (female) | NA |
| Barrett's metaplasia (BM)e | 123 | 65.5 (36–93) | 71% (male) 34% (female) | NA |
| BM with high-grade dysplasia (HGD) | 60 | 66 (46–80) | 89% (male) 11% (female) | NA |
| Normal gastric (GAST) | 14 | 63 (36–82) | 85% (male) 15% (female) | NA |
| Total | 832 |
a
11% of EACs were gastroesophageal junctional adenocarcinomas.
b
Median surveillance of 9 years, ranging from 6 to 22 years.
c
Each of the 11 normal SQ samples was obtained from respective EAC patients included in the RNA sequencing.
d
13% of EACs were gastroesophageal junctional adenocarcinomas.
e
Clinical follow-up information unavailable (progression status unknown) for these patients.